Physician profile
Mubasher Malik
NPI 1225341050
$5,174.20
in general payments reported to CMS, 2019-2025
26 companies · $1,523 in 2025
The $1,523 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $65.75 · 2021: $96.73 · 2022: $635 · 2023: $1,502 · 2024: $1,077 · 2025: $1,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,102.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,272.26 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $1,255.42 | 2022-2025 | |
| Glaxosmithkline, LLC. | $753.47 | 2020-2025 | Benlysta |
| Ucb, INC. | $278.67 | 2019-2025 | Bimzelx, Cimzia, Fintepla |
| Astrazeneca Pharmaceuticals LP | $251.43 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $219.52 | 2022-2025 | Taltz, Zepbound |
| Pfizer INC. | $149.21 | 2022-2025 | |
| Janssen Biotech, INC. | $128.41 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Organon LLC | $111.46 | 2022-2024 | Renflexis |
| Novartis Pharmaceuticals Corporation | $102.26 | 2019-2023 | |
| Genentech USA, INC. | $80.71 | 2019-2025 | Gazyva |
| Aurinia Pharma U.S., INC. | $70.07 | 2022-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $68.23 | 2024-2025 | Orencia |
| Genzyme Corporation | $64.38 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.46 | 2020-2025 | Ofev |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $49.36 | 2023-2024 | Idacio |
| Actelion Pharmaceuticals US, INC. | $39.32 | 2023 | Uptravi, Opsumit |
| Mallinckrodt Hospital Products INC. | $36.88 | 2020 | |
| Alexion Pharmaceuticals, INC. | $36.59 | 2021-2025 | Strensiq |
| Sk Life Science, INC. | $33.24 | 2025 | |
| Sandoz INC. | $24.85 | 2024 | Hyrimoz |
| Sobi, INC | $23.64 | 2023 | |
| Mylan Institutional INC. | $18.23 | 2023 | |
| Horizon Therapeutics Plc | $15.50 | 2022 | |
| Celgene Corporation | $15.02 | 2019 | |
| Hikma Pharmaceuticals USA | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mubasher Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.